The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches
Open accessAbstract
Small, dense low density lipoprotein (sdLDL) represents an emerging cardiovascular risk factor, since these particles can be associated with cardiovascular disease (CVD) independently of established risk factors, including plasma lipids. Obese subjects frequently have atherogenic dyslipidaemia, including elevated sdLDL levels, in addition to elevated triglycerides (TG), very low density lipoprotein (VLDL) and apolipoprotein-B, as well as decreased high density lipoprotein cholesterol (HDL-C) levels. Obesity-related co-morbidities, such as metabolic syndrome (MetS) are also characterized by dyslipidaemia. Therefore, agents that favourably modulate LDL subclasses may be of clinical value in these subjects. Statins are the lipid-lowering drug of choice. Also, anti-obesity and lipid lowering drugs other than statins could be useful in these patients. However, the effects of anti-obesity drugs on CVD risk factors remain unclear. We review the clinical significance of sdLDL in being overweight and obesity, as well as the efficacy of anti-obesity drugs on LDL subfractions in these individuals; a short comment on HDL subclasses is also included. Our literature search was based on PubMed and Scopus listings. Further research is required to fully explore both the significance of sdLDL and the efficacy of anti-obesity drugs on LDL subfractions in being overweight, obesity and MetS. Improving the lipoprotein profile in these patients may represent an efficient approach for reducing cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37385 · Cited by 1,765
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392 · cited 1×
“decreased sdLDL proportion [79,80], whereas in combination with ezetimibe or fenofibrate, a non-significant reduction in sdLDL was observed [65].”
BackgroundWei, M. (1999) · JAMA · doi:10.1001/jama.282.16.1547 · Cited by 1,168
Metabolic origins and clinical significance of LDL heterogeneity
Berneis, K. K., & Krauss, R. M. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200004-jlr200 · Cited by 896
Bugianesi, E., Gastaldelli, A., Vanni, E., Gambino, R., Cassader, M., Baldi, S., Ponti, V., Pagano, G., Ferrannini, E., & Rizzetto, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1682-x · Cited by 770
Overproduction of large VLDL particles is driven by increased liver fat content in man
Adiels, M., Taskinen, M.-R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., Vehkavaara, S., Häkkinen, A., Olofsson, S.-O., Yki-Järvinen, H., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0125-z · Cited by 690
Atherogenic Lipoprotein Particles in Atherosclerosis
Carmena, R., Duriez, P., & Fruchart, J.-C. (2004) · Circulation · doi:10.1161/01.cir.0000131511.50734.44 · Cited by 494 · cited 1×
“still debated whether LDL particle size is an independent CVD risk factor after adjustment for TG and HDL-C levels [21].”
BackgroundBhutani, S., Klempel, M. C., Kroeger, C. M., Trepanowski, J. F., & Varady, K. A. (2013) · Obesity · doi:10.1002/oby.20353 · Cited by 349
Nieves, D. J., Cnop, M., Retzlaff, B., Walden, C. E., Brunzell, J. D., Knopp, R. H., & Kahn, S. E. (2003) · Diabetes · doi:10.2337/diabetes.52.1.172 · Cited by 281 · cited 1×
“increased LDL-C levels is not typical, elevated sdLDL levels with lower large LDL concentrations are associated with reduced insulin sensitivity and increased adiposity [17–19].”
BackgroundPattyn, N., Cornelissen, V. A., Eshghi, S. R. T., & Vanhees, L. (2013) · Sports Medicine · doi:10.1007/s40279-012-0003-z · Cited by 266
Cited by
Samson, S. L., & Garber, A. J. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.09.009 · Cited by 746
Non-alcoholic fatty liver disease and dyslipidemia: An update
Katsiki, N., Mikhailidis, D. P., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.05.003 · Cited by 564
Self-citationSmall Dense Low‐Density Lipoprotein as Biomarker for Atherosclerotic Diseases
Ivanova, E. A., Myasoedova, V. A., Melnichenko, A. A., Grechko, A. V., & Orekhov, A. N. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/1273042 · Cited by 457
Volanesorsen: A New Era in the Treatment of Severe Hypertriglyceridemia
Kolovou, G., Kolovou, V., & Katsiki, N. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040982 · Cited by 33
Self-citationThe lipid paradox in neuroprogressive disorders: Causes and consequences
Morris, G., Berk, M., Walder, K., O’Neil, A., Maes, M., & Puri, B. K. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.06.017 · Cited by 17
Metadata
- Authors
- Nikolic, D., Katsiki, N., Montalto, G., Isenovic, E., Mikhailidis, D., & Rizzo, M.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2013-03-18
- Volume
- 5
- Issue
- 3
- Pages
- 928-948
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W1964997738
- Cited by
- 159
- References
- 23
- FWCI
- 17.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches. https://app.cochat.ai/papers/10.3390/nu5030928
- The paper
- Nikolic, D., Katsiki, N., Montalto, G., Isenovic, E., Mikhailidis, D., & Rizzo, M. (2013). Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches. Nutrients. https://doi.org/10.3390/nu5030928
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.